MAYO CLINIC

1-800-533-1710

BA190

BCR/ABL1, p190, Quant, Monitor

PATIENT NAME				ORDER NUMBER
TESTINGRNV, INTERFACE				**I109000356**
PATIENT ID SA00119496	DATE OF BIRTH 01/01/1999	SEX Male	REQUESTED BY CLIENT CLIENT	
COLLECTED 4/8/2019, 12:00 AM	RECEIVED 4/9/2019, 3:16 PM	REPORTED 4/9/2019, 3:46 PM		
7028846 DLMP Rochester Rochester MN 55901			CLIENT ORDER NUMBER SA00119496 CLIENT MRN SA00119496	

BCR/ABL1 p190 Result	**see interpretation**
Specimen Type	**Bone marrow**

INTERPRETATION

Bone marrow, *BCR/ABL1* mRNA level analysis (p190 fusion form):

Negative. No *BCR/ABL1* p190 mRNA transcripts were detected (%BCR/ABL1(p190):ABL1=0).

NOTE: Please correlate this result with the original (diagnostic) BCR-ABL1 mRNA transcript type identified in this patient to ensure that the ordered test is correct and appropriate for the clinical indication. This assay specifically detects the p190 (e1-a2) BCR-ABL1 transcript isoform. It does not detect the BCR-ABL1 p210 (e13/e14-a2) transcript (prevalent in chronic myeloid leukemia and in some cases of B-lymphoblastic leukemia), or other rare BCR-ABL1 transcript isoforms.

Method summary:
BCR/ABL1, p190 fusion: *BCR/ABL1* p190 mRNA transcript level was evaluated using quantitative, reverse transcription PCR. The detection limit for this assay is 0.01%. See Mayo Clinic Laboratories Test Catalog for additional method details. The assay detects the most common p190 fusion form (e1/a2), but does not detect other fusions, including the p210, which is the most common form found in chronic myelogenous leukemia. This assay should only be ordered for monitoring patients with a previously identified p190 fusion form. Test BADX (BCR/ABL1 mRNA detection, RT-PCR, Quantitative, Diagnostic) should be ordered if the test is being performed in a diagnostic setting to identify the *BCR/ABL1* fusion form and test BCRAB (BCR/ABL1, p210, mRNA detection, RT-PCR, Quantitative, Monitoring CML) should be ordered if this patient is being monitored for a known p210 fusion form (e13a2 or e14a2). The reproducibility of this assay is such that results within 0.5 log should be considered equivalent. Trends in the level of *BCR/ABL1* mRNA should be followed and clinically significant changes verified with a subsequent specimen. Please contact the Mayo Molecular Hematopathology Laboratory at 855-516-8404 with questions or if additional testing is required.

Signing Pathologist: BENJAMIN BAILEY

DISCLAIMER

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

BA190

BCR/ABL1, p190, Quant, Monitor

PATIENT NAME			ORDER NUMBER
TESTINGRNV, INTERFACE			**I109000356**
PATIENT ID SA00119496	DATE OF BIRTH 01/01/1999	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 4/8/2019, 12:00 AM	RECEIVED 4/9/2019, 3:16 PM	REPORTED 4/9/2019, 3:46 PM	
7028846 DLMP Rochester Rochester MN 55901			CLIENT ORDER NUMBER SA00119496 CLIENT MRN SA00119496



MAYO CLINIC

1-800-533-1710

BA190

BCR/ABL1, p190, Quant, Monitor

PATIENT NAME			ORDER NUMBER
TESTINGRNV, INTERFACE			**I109000356**
PATIENT ID SA00119496	DATE OF BIRTH 01/01/1999	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 4/8/2019, 12:00 AM	RECEIVED 4/9/2019, 3:16 PM	REPORTED 4/9/2019, 3:46 PM	
7028846 DLMP Rochester Rochester MN 55901			CLIENT ORDER NUMBER SA00119496 CLIENT MRN SA00119496

CODE	LABORATORY	ADDRESS			
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW	Rochester	, MN	55905

The collected, received, and reported dates and times on the report are in the time zone of the performing location.